Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in CYP?
Cynata Therapeutics: THE INVESTMENT CASE

Cynata Therapeutics: Access latest PPT from Proactive's CEO Sessions

Dr Ross Macdonald talked stemcell research with investors.
Cynata Therapeutics: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: CYP The Big Picture
Dr Ross Macdonald, CEO, Cynata Therapeutics

Cynata Therapeutics' (ASX:CYP) CEO, Dr Ross Macdonald, joined Proactive's CEO Sessions in Sydney on Tuesday 14th March and Melbourne on Wednesday 15th March.

Cynata is now in a transition to a clinical stage company, with the focus on stem cells and regenerative medicine.

Earlier this year Cynata announced a breakthrough strategic partnership with Fujifilm which included the Japanese company investing in the company to become the largest shareholder.

 

ACCESS THE FULL PRESENTATION HERE



Register here to be notified of future CYP Company articles
View full CYP profile View Profile

Cynata Therapeutics Timeline

Newswire
January 19 2017

Related Articles

Cells
May 17 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
1-Operation.jpg
January 19 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
pregnant woman sitting in park
June 13 2017
The £225,000 order is from HuanZhong Biotech, Concepta’s partner in China

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use